GAITHERSBURG, Md., May 1, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its first quarter 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, May 8, 2025. Details of the event and replay are as follows: Conference call details: Date: May 8, 2025 Time: 8:30 a.m. U.S. ET URL to register phone: https://emportal.ink/43UHjFq Dial-in number: (800) 836-8184 (Domestic) or (+1) (646) 357-8785 (International) Webcas ...

Charles Newton Charles Newton "Charles brings a wealth of expertise across corporate finance and capital markets to Novavax," said John C. Jacobs, President and Chief Executive Officer, Novavax. "The knowledge he brings to our already experienced board will be invaluable as we continue to execute our corporate growth strategy focused on forging strategic partnerships for our R&D assets and our Matrix-M® adjuvant." Mr. Newton currently serves as Chief Financial Officer of Lyell Immunopharma, with past leader ...

智通财经4月26日电，诺瓦瓦克斯估计下挫9%，FDA要求该公司进行新一轮临床试验，以推进延迟推出 的新冠病毒疫苗。 ...

美国食品药品管理局（FDA）：要求诺瓦瓦克斯针对被推迟的新冠疫苗接种完成新的临床试验。 ...

Group 1: Novavax Overview - Novavax (NVAX) shares increased by 19.5% to close at $7.47, following a notable trading volume compared to typical sessions, despite a 17.3% loss over the past four weeks [1] - The rise in share price is linked to the FDA's request for additional data on its protein-based COVID-19 vaccine, indicating progress in the regulatory process, although it suggests a delay in full approval [2] Group 2: Financial Expectations - Novavax is expected to report quarterly earnings of $0.19 per share, reflecting a year-over-year increase of 118.1%, while revenues are projected to be $71.84 million, a decrease of 23.5% from the previous year [3] - The consensus EPS estimate for Novavax has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] Group 3: Industry Context - Novavax operates within the Zacks Medical - Biomedical and Genetics industry, where another company, BioNTech SE, saw its shares rise by 9.7% to $114.83, with a 7.9% return over the past month [4] - BioNTech's consensus EPS estimate has changed by +8.5% to -$2.77, representing a significant decline of 95.1% from the previous year, and it also holds a Zacks Rank of 3 (Hold) [5]

Novavax, Inc. NAVX stock traded higher on Wednesday.In an SEC filing, Novavax said, “We believe that our Biologics License Application (BLA) is approvable based on conversations with U.S. Food and Drug Administration (FDA), as of our Prescription Drug User Fee Act date on April 1 and through today.”The company said that it received formal communication from the FDA in the form of an information request for a post-marketing commitment to generate additional clinical data.Also Read: Despite Headwinds, Biotech ...

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive's content includes insights across various sectors such as biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] Group 2 - Proactive is committed to adopting technology to enhance workflows and content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Company Performance - Novavax closed at $6.01, with a slight increase of +0.17% on the most recent trading day, outperforming the S&P 500's loss of 2.36% [1] - Over the past month, Novavax shares have decreased by 21.05%, which is significantly worse than the Medical sector's loss of 9.83% and the S&P 500's loss of 5.6% [1] Earnings Estimates - Analysts expect Novavax to report an EPS of $0.19, representing a substantial increase of 118.1% compared to the same quarter last year [2] - The Zacks Consensus Estimate for revenue is projected at $71.84 million, reflecting a decrease of 23.47% from the previous year [2] - For the full year, earnings are projected at $0.75 per share, indicating a growth of 160.98%, while revenue is expected to decline by 21.39% to $536.24 million [3] Analyst Projections - Recent shifts in analyst projections for Novavax should be monitored, as positive estimate revisions are generally seen as favorable for the company's business outlook [4] - Empirical research shows that estimate revisions correlate with stock price performance, which is utilized in the Zacks Rank model [5] Zacks Rank and Valuation - Novavax currently holds a Zacks Rank of 3 (Hold), with the Zacks Consensus EPS estimate having increased by 579.09% in the past month [6] - The company has a Forward P/E ratio of 7.97, which is below the industry average of 15.7 [7] - Novavax's PEG ratio stands at 0.15, significantly lower than the industry average PEG ratio of 1.25 [8] Industry Context - The Medical - Biomedical and Genetics industry, which includes Novavax, has a Zacks Industry Rank of 72, placing it in the top 30% of over 250 industries [9]

Novavax (NVAX) closed the most recent trading day at $6.39, moving -0.31% from the previous trading session. This move lagged the S&P 500's daily loss of 0.17%. Meanwhile, the Dow experienced a drop of 0.39%, and the technology-dominated Nasdaq saw a decrease of 0.05%.Shares of the vaccine maker witnessed a loss of 23.51% over the previous month, trailing the performance of the Medical sector with its loss of 6.9% and the S&P 500's loss of 3.94%.The investment community will be closely monitoring the perfor ...

Core Insights - Novavax's non-mRNA JN.1 COVID-19 vaccine shows lower frequency and severity of short-term side effects compared to Pfizer-BioNTech's mRNA vaccine, with full results to be published later this year [1][3][4] Group 1: Study Findings - The SHIELD-Utah study indicates that Novavax recipients reported an average of 1.7 symptoms, while Pfizer-BioNTech recipients reported 2.8 symptoms [3] - 43.8% of Pfizer-BioNTech recipients experienced at least one symptom of Grade 2 or higher, compared to 24.2% of Novavax recipients [3] - Local reactogenicity events were 12.5% fewer in Novavax recipients compared to Pfizer-BioNTech recipients [3] - Novavax recipients experienced lower hours of reduced activity, with means of 0.7 hours missed work and 0.8 hours less productivity, compared to 1.4 hours and 2.4 hours for Pfizer-BioNTech recipients, respectively [3] Group 2: Company Strategy and Technology - Novavax focuses on leveraging its scientific expertise in vaccines and its technology platform, which includes protein-based nanoparticles and the Matrix-M adjuvant [5] - The company aims to build new partnerships through out-licensing its technology and vaccine assets, with a growing early-stage pipeline [5] - The SHIELD-Utah study adds to the body of research supporting the tolerability of Novavax's COVID-19 vaccine [4]